Abstract
Background Hypertrophic cardiomyopathy (HCM) patients with massive left ventricular hypertrophy (LVH) (hereby defined as maximal LV wall thickness >30mm) are known to have lower rates of survival. Recently, contrast-enhanced cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) has emerged as a potential novel marker of increased cardiovascular risk in HCM. Methods Cine CMR and LGE imaging were performed on HCM patients with massive LV hypertrophy and compared with those with a maximal LV wall thickness <30mm. Results Among 902 consecutive HCM patients, 40 (4.4%) had a maximal LV wall thickness of ≥ 30mm (mean thickness 33.7± 4.2mm, range 30 - 50mm, 23% females) with a mean age of 37 ± 18 years old, including 11 patients (28%) ≥ 50 years of age. When compared to those with a maximal wall thickness less than 30mm, these patients were significantly younger (mean age 37 ± 18 vs 47 ± 18, p<0.001) and had a similar proportion of males (77.5% versus 66.8%, p=0.16). Mean left ventricular mass was significantly higher (317 ± 142 versus 163 ± 62 grams, p<0.001). They also had significantly higher LV end diastolic volume (LVEDV) (169.6 ± 58.5 versus 153.0 ± 42.1 mL, p<0.01) and LV end systolic volume
Highlights
Hypertrophic cardiomyopathy (HCM) patients with massive left ventricular hypertrophy (LVH) are known to have lower rates of survival
Cine cardiac magnetic resonance (CMR) and late gadolinium enhancement (LGE) imaging were performed on HCM patients with massive LV hypertrophy and compared with those with a maximal LV wall thickness
1cardiology, BIDMC, Boston, MA, USA Full list of author information is available at the end of the article (LVESV) (63.0± 40.8 versus 49.9 ± 23.1 ml, p=0.001)
Summary
Characterization of patients with massive hypertrophic cardiomyopathy using contrastenhanced magnetic resonance imaging: does contrast provide additional information?. Raymond H Chan1*, Susie Hong, Tammy S Haas, Kristin Feeney, John Lesser, Michael C Gibson, Warren J Manning, Barry J Maron, Martin Maron, Evan Appelbaum
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.